“Moderna’s mRNA Technology: Revolutionizing Vaccines Against COVID-19 and the Importance of Vaccinations”

Moderna pioneering biotechnology company and leader in mRNA technology, has managed to impact the world population with more than 1 billion doses of vaccines against COVID-19.

The company, which designed, developed and obtained approval of its first vaccine against this disease in record time, managed to rank third worldwide among the most widely used vaccines to combat this virus, being one of the first and most effective .

Therefore, within the framework of the 21st Vaccination Week in the Americas (SVA), Asofarma highlights the importance of vaccines with mRNA technology, carried out by Moderna, in addition to its most significant findings, without neglecting the continuing need for the world population to continue vaccinating against this virus, knowing that vaccines save millions of lives every anus.

According to Dr. Yamile Sandoval Sánchez, medical manager of the Asofarma Vaccine Unit, it is necessary to continue reinforcing in the population the importance of vaccination against COVID-19 and, therefore, this type of spaces such as VWA They are ideal for urging each of the countries to make this a priority and even begin to have a supply of vaccines for children from 6 months of age.

Relevant data from Moderna’s vaccine against COVID-19:

Moderna has provided more than 1 billion doses of COVID-19 vaccines

Creation in record time thanks to its mRNA technology

· Top three worldwide of the most used vaccines to combat this disease

Creation of bivalent vaccine

mRNA technology

It was designed using the sequence of the virus, not by inserting a weakened or inactivated version of it. They contain instructions on how to create a protein that mimics a part of the new virus. With this plan, the body’s cells build proteins and display them to the immune system. Immune cells notice that these are foreign proteins and react to mount an immune response to protect themselves against the virus.

Moderna’s commitment to research and development of innovative vaccines has continued to advance. The emergence of new variants such as Ómicron, which became the most prevalent and highly infectious variant of interest, led the company to reformulate its existing COVID-19 vaccine to adapt it and more effectively deal with this circulating strain, in addition to providing protection against the original Wuhan strain.

“Currently we have had many achievements, however, the fight does not end, we need the various countries to have a public health priority action both in children and adults, since not everyone has access to vaccines, therefore, we call within the framework of the 21st Vaccination Week in the Americas”, concluded the specialist.